OBJECTIVE: Due to a lack of sufficient data, the treatment protocols for male breast cancer are usually the same as those used for female breast cancer. The aim of the current study was to present our clinical experience with male breast cancer. MATERIALS AND METHODS: The records of 37 patients who were treated for male breast cancer in our hospital between 2004 and 2014 were reviewed retrospectively. The data of patients were recorded and analyzed. RESULTS: The mean age of the patients was 63.03±12.36 years. Thirty-three patients (89.2%) had invasive ductal carcinoma, two (5.4%) had ductal carcinoma in situ, and two had invasive lobular carcinoma (5.4%). The most common molecular subtype was luminal A (17 cases, 45.9%). Twenty-nine patients with male breast cancer underwent mastectomy and two underwent breast conserving surgery. Axillary lymph node dissection was performed in 25 patients. The most common surgical procedure was modified radical mastectomy. Distant metastases were present in 17 (45.9%) patients. Overall, the 5-year survival was 60%. The 5-year survival was 100% for those with stage 0-I disease, 87% for stage II, and 42% for stage III. The 3-year survival was 14% for stage IV. CONCLUSION: Patients with male breast cancer presented at an older age, a later stage, and with earlier metastasis. Early metastasis and death increases with increasing stage. Poor prognosis correlates with late admission. Data from different centers should be compiled and reviewed in order to determine a specific treatment protocol for male breast cancer; each paper published reveals new data.
OBJECTIVE: Due to a lack of sufficient data, the treatment protocols for male breast cancer are usually the same as those used for female breast cancer. The aim of the current study was to present our clinical experience with male breast cancer. MATERIALS AND METHODS: The records of 37 patients who were treated for male breast cancer in our hospital between 2004 and 2014 were reviewed retrospectively. The data of patients were recorded and analyzed. RESULTS: The mean age of the patients was 63.03±12.36 years. Thirty-three patients (89.2%) had invasive ductal carcinoma, two (5.4%) had ductal carcinoma in situ, and two had invasive lobular carcinoma (5.4%). The most common molecular subtype was luminal A (17 cases, 45.9%). Twenty-nine patients with male breast cancer underwent mastectomy and two underwent breast conserving surgery. Axillary lymph node dissection was performed in 25 patients. The most common surgical procedure was modified radical mastectomy. Distant metastases were present in 17 (45.9%) patients. Overall, the 5-year survival was 60%. The 5-year survival was 100% for those with stage 0-I disease, 87% for stage II, and 42% for stage III. The 3-year survival was 14% for stage IV. CONCLUSION:Patients with male breast cancer presented at an older age, a later stage, and with earlier metastasis. Early metastasis and death increases with increasing stage. Poor prognosis correlates with late admission. Data from different centers should be compiled and reviewed in order to determine a specific treatment protocol for male breast cancer; each paper published reveals new data.
Entities:
Keywords:
Breast cancer; diagnosis; disease management; male
Authors: Larissa A Korde; Jo Anne Zujewski; Leah Kamin; Sharon Giordano; Susan Domchek; William F Anderson; John M S Bartlett; Karen Gelmon; Zeina Nahleh; Jonas Bergh; Bruno Cutuli; Giancarlo Pruneri; Worta McCaskill-Stevens; Julie Gralow; Gabriel Hortobagyi; Fatima Cardoso Journal: J Clin Oncol Date: 2010-03-22 Impact factor: 44.544
Authors: B Cutuli; M Lacroze; J M Dilhuydy; M Velten; B De Lafontan; C Marchal; M Resbeut; Y Graic; F Campana; V Moncho-Bernier Journal: Eur J Cancer Date: 1995-11 Impact factor: 9.162
Authors: Robert Kornegoor; Cathy B Moelans; Anoek Hj Verschuur-Maes; Marieke Ch Hogenes; Peter C de Bruin; Joost J Oudejans; Paul J van Diest Journal: Breast Cancer Res Date: 2012-07-05 Impact factor: 6.466
Authors: Parhom Towfighi; Romina Deldar; Zoe K Haffner; Nathan Aminpour; Olutayo Sogunro; Areeg A Abu El Hawa; Marc Boisvert; Kenneth L Fan Journal: Breast Cancer Res Treat Date: 2022-05-27 Impact factor: 4.872